Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth KnowingZacks Investment Research • 03/19/24
Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca TakeoverInvestors Business Daily • 03/19/24
AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it gettingProactive Investors • 03/19/24
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancerBusiness Wire • 03/19/24
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research • 03/18/24
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolioBusiness Wire • 03/18/24
Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZenecaBusiness Wire • 03/14/24
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPDBusiness Wire • 03/13/24